Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

Inclusion Criteria: * 18-65 years * histologically confirmed de novo Non Hodgkin's lymphoma (except highly aggressive lymphoma such as lymphoblastic lymphoma and Burkitt lymphoma) * plan to be given 6-8 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ± Rituximab (R) * KPS ≥70 * plan continuous PEG-rhG-CSF or rhG-CSF adiministration after at least 3 cycles of treatment for neutropenia prophylactic treatment * absolute neutrophil count≥1.5×109/L，platelet count ≥100× 109/L，hemoglobin≥90g/L，while blood cell count≥3.0×109/L，without bleeding signs * adquate liver and renal function as protocol discribed * no serious cardiovascular disease as protocol discribed * under good mental conditions and informed consented * potential benefit for subjects based on investigators' decision Exclusion Criteria: * history of hematopoetic stem cell transplantationor organ transplantation * uncontrollable infection * allergic to study drugs or ingredients * accepted any other investigational drug or participated another interventional study within 30 days during screening period * other uncontrollable conditions judged by the investigator * breast-feeding , pregnant or plan to be pregnant during study observation period